IMPACT OF INCLUSION OF FINERENONE IN THE BURDEN OF CHRONIC KIDNEY DISEASE (CKD) IN TYPE 2 DIABETES (T2D) IN COLOMBIA

被引：0
|
作者：
Lopez-Cabra, C. [1 ]
Rodriguez, A. D. [2 ]
Mayorga, Mogollon W. [2 ]
Zuluaga, J. R. [3 ]
Patino, A. [1 ]
Herran, S. E. [3 ]
Marrugo, R. [3 ]
机构：
[1] Bayer, Bogota, Cun, Colombia
[2] Numeris, Bogota, Colombia
[3] Bayer, Bogota, Colombia
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE425
引用
收藏
页码：S137 / S137
页数：1
相关论文
共 50 条
  • [41] Finerenone (Kerendia) for the Treatment of Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus
    Stewart-Lynch, Autumn
    AMERICAN FAMILY PHYSICIAN, 2023, 108 (03) : 305 - 306
  • [42] Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
    Filippatos, Gerasimos
    Anker, Stefan D.
    Pitt, Bertram
    McGuire, Darren K.
    Rossing, Peter
    Ruilope, Luis M.
    Butler, Javed
    Jankowska, Ewa A.
    Michos, Erin D.
    Farmakis, Dimitrios
    Farjat, Alfredo E.
    Kolkhof, Peter
    Scalise, Andrea
    Joseph, Amer
    Bakris, George L.
    Agarwal, Rajiv
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 9 (01) : 85 - 93
  • [43] Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
    Ortiz, Alberto
    Arroyo, Roberto Alcazar
    Escribano, Pedro Pablo Casado
    Fernandez-Fernandez, Beatriz
    Deben, Francisco Martinez
    Mediavilla, Juan Diego
    Michan-Dona, Alfredo
    Soler, Maria Jose
    Gorriz, Jose Luis
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (06) : 519 - 531
  • [44] Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
    Filippatos, Gerasimos
    Anker, Stefan D.
    August, Phyllis
    Coats, Andrew J. S.
    Januzzi, James L.
    Mankovsky, Boris
    Rossing, Peter
    Ruilope, Luis M.
    Pitt, Bertram
    Sarafidis, Pantelis
    Teerlink, John R.
    Kapelios, Chris J.
    Gebel, Martin
    Brinker, Meike
    Joseph, Amer
    Lage, Andrea
    Bakris, George
    Agarwal, Rajiv
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (02) : 183 - 191
  • [45] Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
    Ashjian, Emily
    Clarke, Megan
    Pogue, Kristen
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (23) : 1708 - 1721
  • [46] Blood pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
    Ruilope, Luis M.
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Rossing, Peter
    Sarafidis, Pantelis
    Schmieder, Roland E.
    Joseph, Amer
    Rethemeier, Nicole
    Nowack, Christina
    Bakris, George L.
    HYPERTENSION, 2022, 79 (12) : 2685 - 2695
  • [47] EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D
    Ruilope, Luis
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Rossing, Peter
    Sarafidis, Pantelis
    Schmieder, Roland E.
    Joseph, Amer
    Mentenich, Nicole
    Nowack, Christina
    Bakris, George
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [48] Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
    Pitt, Bertram
    Filippatos, Gerasimos
    Agarwal, Rajiv
    Anker, Stefan D.
    Bakris, George L.
    Rossing, Peter
    Joseph, Amer
    Kolkhof, Peter
    Nowack, Christina
    Schloemer, Patrick
    Ruilope, Luis M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24): : 2252 - 2263
  • [49] Finerenone in Patients with CKD and T2D by SGLT-2i Treatment: An Analysis of the FIDELIODKD Study
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Chan, Juliana
    Kooy, Adriaan
    McCafferty, Kieran
    Schernthaner, Guntram
    Wanne, Christoph
    AMERICAN HEART JOURNAL, 2021, 242 : 160 - 161
  • [50] Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Cherney, David
    Charbonnel, Bernard
    Mcguire, Darren K.
    Cosentino, Francesco
    Shih, Weichung J.
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Raji, Annaswamy
    Gantz, Ira
    DIABETES, 2021, 70
12345